VRDN (Viridian Therapeutics) Cyclically Adjusted Book per Share: $15.07 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VRDN Viridian Therapeutics Inc VRDN
49 GF Score
Price $23.42
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics Cyclically Adjusted Book per Share?

Viridian Therapeutics VRDN +1.41% 49 Cyclically Adjusted Book per Share is $15.07 as of Jun. 2026. GuruFocus rates VRDN with a GF Score™ of 49/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Viridian Therapeutics's adjusted book value per share for the three months ended in Jun. 2026 was $5.229. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $15.07 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Viridian Therapeutics's average Cyclically Adjusted Book Growth Rate was -63.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -26.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Viridian Therapeutics was -26.40% per year. The lowest was -26.40% per year. And the median was -26.40% per year.

As of today (2026-08-11), Viridian Therapeutics's current stock price is $23.415. Viridian Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was $15.07. Viridian Therapeutics's Cyclically Adjusted PB Ratio of today is 1.55.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Viridian Therapeutics was 1.64. The lowest was 0.11. And the median was 0.36.


Viridian Therapeutics  (NAS:VRDN) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Viridian Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=23.415/15.07
=1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Viridian Therapeutics was 1.64. The lowest was 0.11. And the median was 0.36.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Viridian Therapeutics Cyclically Adjusted Book per Share Related Terms


Viridian Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics Cyclically Adjusted Book per Share Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 62.26 106.18 63.64 24.79

Viridian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.10 32.31 24.79 19.36 15.07

VRDN vs BHVN, AGIO, SION: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Viridian Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Viridian Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Cyclically Adjusted PB Ratio falls into.


VRDN
49GF Score
Viridian Therapeutics Inc VRDN
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Viridian Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.229/333.9520*333.9520
=5.229

Current CPI (Jun. 2026) = 333.9520.

Viridian Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 97.625 241.428 135.038
201612 -6.653 241.432 -9.203
201703 33.633 243.801 46.070
201706 28.866 244.955 39.354
201709 26.720 246.819 36.153
201712 25.588 246.524 34.663
201803 36.136 249.554 48.357
201806 33.172 251.989 43.962
201809 29.532 252.439 39.068
201812 24.973 251.233 33.195
201903 19.872 254.202 26.106
201906 16.161 256.143 21.070
201909 11.144 256.759 14.494
201912 6.779 256.974 8.810
202003 7.629 258.115 9.870
202006 5.982 257.797 7.749
202009 5.530 260.280 7.095
202012 -14.362 260.474 -18.413
202103 -7.605 264.877 -9.588
202106 -6.441 271.696 -7.917
202109 2.226 274.310 2.710
202112 2.252 278.802 2.697
202203 2.007 287.504 2.331
202206 1.350 296.311 1.521
202209 6.631 296.808 7.461
202212 6.123 296.797 6.890
202303 5.008 301.836 5.541
202306 4.154 305.109 4.547
202309 3.402 307.789 3.691
202312 4.362 306.746 4.749
202403 6.000 312.332 6.415
202406 5.160 314.175 5.485
202409 6.550 315.301 6.937
202412 5.960 315.605 6.306
202503 5.094 319.799 5.319
202506 3.996 322.561 4.137
202509 3.820 324.800 3.928
202512 5.795 324.054 5.972
202603 4.919 330.213 4.975
202606 5.229 333.952 5.229

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $15.07 mean?
Viridian Therapeutics (VRDN) has a Cyclically Adjusted Book per Share of $15.07 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Viridian Therapeutics and its competitors.
Is Viridian Therapeutics' Cyclically Adjusted Book per Share too high?
Viridian Therapeutics' current Cyclically Adjusted Book per Share is $15.07. Overall, Viridian Therapeutics has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Cyclically Adjusted Book per Share compare to BHVN and AGIO?
Viridian Therapeutics' Cyclically Adjusted Book per Share of $15.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current Cyclically Adjusted Book per Share is $15.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (VRDN) has a current Cyclically Adjusted Book per Share of $15.07. The current Cyclically Adjusted Book per Share is $15.07. Viridian Therapeutics' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Viridian Therapeutics (VRDN), the current Cyclically Adjusted Book per Share is $15.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viridian Therapeutics Business Description

Other Exchanges 0K1R:UK1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
49GF Score

Get the complete analysis for VRDN

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.42
Price